NOX4 and xanthine oxidase inhibitors, mitochondrial antioxidants, dietary modifications, and tolvaptan are potential treatments addressing ROS in cystic kidney disease, yet there is limited randomized controlled trial research performed on humans demonstrating their efficacy and safety. Here, NOX4 is linked to cystic kidney disease.